IVBIY (Innovent Biologics) Cash-to-Debt : 2.52 (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Innovent Biologics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Innovent Biologics's cash to debt ratio for the quarter that ended in Jun. 2024 was 2.52.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Innovent Biologics could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Innovent Biologics's Cash-to-Debt or its related term are showing as below:

IVBIY' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.22 Med: 3.18 Max: 6.67
Current: 2.79

During the past 9 years, Innovent Biologics's highest Cash to Debt Ratio was 6.67. The lowest was 2.22. And the median was 3.18.

IVBIY's Cash-to-Debt is ranked worse than
62.89% of 1482 companies
in the Biotechnology industry
Industry Median: 7.645 vs IVBIY: 2.79

Innovent Biologics Cash-to-Debt Historical Data

The historical data trend for Innovent Biologics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Innovent Biologics Cash-to-Debt Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

6.67

3.18

2.56

2.80

2.79

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial												2.56	2.22	2.80	2.52	2.79

Competitive Comparison of Innovent Biologics's Cash-to-Debt

For the Biotechnology subindustry, Innovent Biologics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Innovent Biologics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Innovent Biologics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1417.297	/	(170.91	+	336.153)
	=	2.80

Innovent Biologics's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1162.896	/	(139.456	+	322.138)
	=	2.52

Innovent Biologics (OTCPK:IVBIY) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Innovent Biologics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (OTCPK:IVBIY) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

IVBXF:USA 01801:Hong Kong 6IB:Germany 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.